HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY2066948

a selective estrogen receptor modulator; structure in first source

Also Known As:

LY 2066948; LY-2066948

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        LY2066948: 3
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - LY2066948: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - LY2066948: 3

Experts

1.	Cohen, Ilene R: 2 articles (10/2005 - 01/2005)
2.	Henck, Judith W: 2 articles (10/2005 - 01/2005)
3.	Rudmann, Daniel G: 2 articles (10/2005 - 01/2005)
4.	Bolton, Judy L: 1 article (03/2012)
5.	Chandrasena, R Esala P: 1 article (03/2012)
6.	Gherezghiher, Teshome B: 1 article (03/2012)
7.	Michalsen, Bradley: 1 article (03/2012)
8.	Qin, Zhihui: 1 article (03/2012)
9.	Sohn, Johann: 1 article (03/2012)
10.	Thatcher, Gregory R J: 1 article (03/2012)

Related Diseases

1.	Weight Gain 10/01/2005 - "Oral administration of LY2066948 to immature rats blocked uterine weight gain induced by ethynyl estradiol with an ED50 of 0.07 mg/kg. Studies in mature rats demonstrated that LY2066948 decreases uterine weight by 51% after 35 d treatment, confirming potent uterine antagonist activity over several estrous cycles. "
2.	Virilism (Virilization) 01/01/2005 - "These studies demonstrate that LY2066948 produces species-specific, androgen-dependent mammary gland virilism in the female rat." 01/01/2005 - "Androgen dependent mammary gland virilism in rats given the selective estrogen receptor modulator LY2066948 hydrochloride."
3.	Myoma 03/05/2012 - "LY2066948, a novel SERM in development by Eli Lilly for the treatment of uterine fibroids and myomas, has structural similarity to the equine estrogen equilenin present in hormone replacement formulations; both contain a naphthol group susceptible to oxidative metabolism to o-quinones. "
4.	Leiomyoma (Uterine Fibroids) 03/05/2012 - "LY2066948, a novel SERM in development by Eli Lilly for the treatment of uterine fibroids and myomas, has structural similarity to the equine estrogen equilenin present in hormone replacement formulations; both contain a naphthol group susceptible to oxidative metabolism to o-quinones. "
5.	Breast Neoplasms (Breast Cancer) 10/01/2005 - "LY2066948 binds with high affinity to both estrogen receptors and has potent estrogen antagonist activity in human uterine and breast cancer cells. "

Related Drugs and Biologics

1.	Ethinyl Estradiol (Estinyl)
2.	Androgens
3.	Selective Estrogen Receptor Modulators (SERM)
4.	Estrogens (Estrogen)
5.	Estrogen Receptors
6.	Quinones
7.	Naphthols
8.	Hormones (Hormone)
9.	Equilenin

Related Therapies and Procedures

1.	Oral Administration